Study for treatment of relapsed or refractory multiple myeloma
Primary disease category: Cancer
Secondary disease categories: Myeloma
Sponsor: Celgene Corporation
Projected enrollment dates: January 2014 to May 2018
Official study title: A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
External link(s):
UA Cancer Center Website